Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Stephania Root (Stephania tetrandra) is a traditional Chinese medicine used for its analgesic, diuretic, and antihypertensive properties [PMID:26899361], primarily characterized by the presence of bisbenzylisoquinoline alkaloids [PMID:35432428].
Contexte
Stephania tetrandra S. Moore, known in Chinese as 'Fen Fang Ji' or 'Fangji', is a plant distributed across tropical and subtropical regions of Asia and Africa [PMID:32336965, PMID:32497674].
Usages traditionnels
It is used in traditional Chinese medicine to treat arthralgia caused by rheumatism, wet beriberi, dysuria, eczema, inflamed sores [PMID:32336965], edema [PMID:32497674], hypertension, asthma, tuberculosis, dysentery, hyperglycemia, malaria, cancer, and fever [PMID:26899361].
Composés actifs
The primary active components are bisbenzylisoquinoline alkaloids, most notably tetrandrine [PMID:26899361, PMID:39151800], fangchinoline [PMID:41242135], and coclaurine [PMID:39458997]. Other isolated compounds include limacine, N-trans-Feruloyltyramine, and Stephtetrandrine A-D [PMID:34348525].
Mécanisme d'action
Tetrandrine acts as a calcium channel blocker [PMID:26899361] and interacts with M receptors for cardiovascular effects [PMID:12466045]. It modulates signaling pathways including reactive oxygen species (ROS), autophagic flux, the caspase pathway, and targets SIRT5 to induce ER stress in melanoma cells [PMID:26899361, PMID:39850232]. Coclaurine inhibits EFHD2, downregulating the NOX4-ABCC1 signaling pathway [PMID:39458997]. Fangchinoline targets FAU to induce senescence in circulating tumor cells [PMID:41242135].
Preuves cliniques
Preuve BHypertension
Tetrandrine has been found effective in clinical trials for the treatment of hypertension [PMID:26899361, PMID:12466045].
Preuve BSilicosis and Lung Cancer
Clinical trials indicated tetrandrine is effective against silicosis, inflammation, and lung cancer without toxicity [PMID:26899361].
Preuve CDiabetic Kidney Disease (DKD)
S. tetrandra demonstrates value in preventing and treating DKD by regulating inflammatory responses, antagonizing oxidative stress, and improving glomerular endothelial function [PMID:41031161].
Preuve DNephrotic Syndrome
A herbal pair of S. tetrandra and Astragalus membranaceus reduced serum triglycerides, total cholesterol, IL-6, BUN, and urinary protein in rat models [PMID:36678585].
Preuve DPulmonary Fibrosis
Tetrandrine alleviated pulmonary fibrosis in mice by regulating lung microbial communities and ameliorating alveolar epithelial cell senescence [PMID:39510818].
Preuve D
Sécurité et effets indésirables
While tetrandrine is described as minimally toxic [PMID:39510818], some reviews list S. tetrandra as a source of renal toxic alkaloids [PMID:26670420]. A critical safety concern is the frequent adulteration or substitution of S. tetrandra with the nephrotoxic and carcinogenic Aristolochia fangchi [PMID:26632529, PMID:18404356]. This substitution has led to 'Chinese-herb nephropathy', characterized by progressive interstitial fibrosis, end-stage renal disease, and urothelial carcinoma [PMID:12505369, PMID:10841870, PMID:9090927].
Synthèse des preuves
Evidence ranges from high-level clinical trial reports for hypertension and silicosis to preclinical animal and cellular studies for oncology and renal protection. A significant portion of the literature focuses on the critical need for quality control to prevent toxic substitution with Aristolochia species.
2.PMID: 26632529 (2016) — Differentiation between two "fang ji" herbal medicines, Stephania tetrandra and the nephrotoxic Aristolochia fangchi, using hyperspectral imaging. · Phytochemistry
3.PMID: 41031161 (2025) — Stephania tetrandra S. Moore: a promising candidate drug for treating diabetic kidney disease. · Frontiers in pharmacology
4.PMID: 39850232 (2024) — Tetrandrine targeting SIRT5 exerts anti-melanoma properties via inducing ROS, ER stress, and blocked autophagy. · Journal of pharmaceutical analysis
5.PMID: 32336965 (2020) — A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).
Sources gouvernementales
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
Tetrandrine targets SIRT5 to exert anti-melanoma properties [PMID:39850232], and fangchinoline inhibits systemic metastasis by inducing senescence of circulating tumor cells [PMID:41242135].
· Phytochemistry reviews : proceedings of the Phytochemical Society of Europe
6.PMID: 34348525 (2023) — Stephtetrandrine A-D, bisbenzylisoquinoline alkaloids from Stephania tetrandra. · Natural product research
7.PMID: 9090927 (1997) — Belgian (Chinese herb) nephropathy: why? · Journal de pharmacie de Belgique
8.PMID: 39151800 (2024) — Development of Stephania tetrandra S. MOORE hairy root culture process for tetrandrine production. · Journal of biotechnology
9.PMID: 32497674 (2020) — History of uses, phytochemistry, pharmacological activities, quality control and toxicity of the root of Stephania tetrandra S. Moore: A review. · Journal of ethnopharmacology
10.PMID: 12505369 (2002) — Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). · Toxicology
11.PMID: 40383618 (2025) — A CYP80B enzyme from Stephania tetrandra enables the 3'-hydroxylation of N-methylcoclaurine and coclaurine in the biosynthesis of benzylisoquinoline alkaloids. · Chinese journal of natural medicines
12.PMID: 18418355 (2008) — Aristolochic acid nephropathy: a worldwide problem. · Kidney international
13.PMID: 33426289 (2020) — The complete chloroplast genome of Stephania tetrandra (Menispermaceae). · Mitochondrial DNA. Part B, Resources
14.PMID: 21322952 (2010) — [Comparative study on metabonomics and on liver and kidney toxicity of Aristolochia fangchi and Stephania tetrandra]. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
15.PMID: 39458997 (2024) — Stephania tetrandra and Its Active Compound Coclaurine Sensitize NSCLC Cells to Cisplatin through EFHD2 Inhibition. · Pharmaceuticals (Basel, Switzerland)
16.PMID: 35432428 (2022) — Transcriptome Analysis of Stephania tetrandra and Characterization of Norcoclaurine-6-O-Methyltransferase Involved in Benzylisoquinoline Alkaloid Biosynthesis. · Frontiers in plant science
17.PMID: 23597204 (2013) — Mechanisms of herb-induced nephrotoxicity. · Current medicinal chemistry
18.PMID: 10841870 (2000) — Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). · The New England journal of medicine
19.PMID: 29507594 (2018) — Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments. · Evidence-based complementary and alternative medicine : eCAM
20.PMID: 39510818 (2025) — Tetrandrine Alleviates Pulmonary Fibrosis by Modulating Lung Microbiota-Derived Metabolism and Ameliorating Alveolar Epithelial Cell Senescence. · Phytotherapy research : PTR
24.PMID: 18404356 (2008) — Authentication of Stephania tetrandra S. Moore (Fang Ji) and differentiation of its common adulterants using microscopy and HPLC analysis. · Journal of natural medicines
25.PMID: 31103904 (2019) — Natural products as multidrug resistance modulators in cancer. · European journal of medicinal chemistry
26.PMID: 30548302 (2019) — Recognition of the toxicity of aristolochic acid. · Journal of clinical pharmacy and therapeutics
27.PMID: 31924150 (2020) — Radix Stephaniae Tetrandrine: An Emerging Role for Management of Breast Cancer. · Current pharmaceutical design
28.PMID: 26670420 (2016) — Renal toxic ingredients and their toxicology from traditional Chinese medicine. · Expert opinion on drug metabolism & toxicology
29.PMID: 40333917 (2025) — Media Composition Effects on Hairy Root Biomass and Tetrandrine Production in Stephania tetrandra. · Molecules (Basel, Switzerland)
30.PMID: 32163850 (2020) — Comprehensive profiling of Stephania tetrandra (Fangji) by stepwise DFI and NL-dependent structure annotation algorithm-based UHPLC-Q-TOF-MS and direct authentication by LMJ-HRMS. · Journal of pharmaceutical and biomedical analysis